CL2019000951A1 - Producción de partículas re-188/186 - Google Patents

Producción de partículas re-188/186

Info

Publication number
CL2019000951A1
CL2019000951A1 CL2019000951A CL2019000951A CL2019000951A1 CL 2019000951 A1 CL2019000951 A1 CL 2019000951A1 CL 2019000951 A CL2019000951 A CL 2019000951A CL 2019000951 A CL2019000951 A CL 2019000951A CL 2019000951 A1 CL2019000951 A1 CL 2019000951A1
Authority
CL
Chile
Prior art keywords
particles
activated
particle production
isotopes
composition
Prior art date
Application number
CL2019000951A
Other languages
English (en)
Inventor
Tuomo Nikula
Thomas Wendler
Original Assignee
Oncobeta Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobeta Int Gmbh filed Critical Oncobeta Int Gmbh
Publication of CL2019000951A1 publication Critical patent/CL2019000951A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/04—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators
    • G21G1/06—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by neutron irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N5/1028—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy using radiation sources applied onto the body
    • A61N5/1029—Radioactive dressings
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
    • G21H1/00—Arrangements for obtaining electrical energy from radioactive sources, e.g. from radioactive isotopes, nuclear or atomic batteries
    • G21H1/06—Cells wherein radiation is applied to the junction of different semiconductor materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Se proporciona un proceso para producir partículas activadas que comprenden isótopos de 188Re y/o isótopos de 186 Re mediante la irradiación con neutrones de partículas de partida no volátiles e insolubles en agua que comprenden un compuesto de renio. Además, se proporciona un proceso para producir las correspondientes partículas de partida no volátiles e insolubles en agua. Además, se proporcionan las respectivas partículas de partida y partículas activadas, respectivamente, y una composición que comprende una pluralidad de partículas activadas. Las partículas activadas y la composición que las comprende son adecuadas para su uso en la terapia con radionúclidos y para aplicaciones cosméticas.
CL2019000951A 2016-10-10 2019-04-09 Producción de partículas re-188/186 CL2019000951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102016119239.2A DE102016119239A1 (de) 2016-10-10 2016-10-10 Partikel und Zusammensetzung, die Rheniumverbindungen umfassen, und Prozesse zum Erhalten solcher Produkte

Publications (1)

Publication Number Publication Date
CL2019000951A1 true CL2019000951A1 (es) 2019-09-27

Family

ID=60164670

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000951A CL2019000951A1 (es) 2016-10-10 2019-04-09 Producción de partículas re-188/186

Country Status (15)

Country Link
US (1) US11135323B2 (es)
EP (1) EP3523811B1 (es)
KR (1) KR102488513B1 (es)
CN (1) CN110168669B (es)
AU (1) AU2017343616B2 (es)
BR (1) BR112019007308A2 (es)
CA (1) CA3039834A1 (es)
CL (1) CL2019000951A1 (es)
CO (1) CO2019004738A2 (es)
DE (1) DE102016119239A1 (es)
IL (1) IL265932B (es)
NZ (1) NZ752287A (es)
PL (1) PL3523811T3 (es)
RU (1) RU2749141C2 (es)
WO (1) WO2018069329A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854757A1 (en) 2020-01-23 2021-07-28 Technische Universität München Rhenium sulfide particles and microwave assisted process for their preparation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2972531A (en) * 1958-04-18 1961-02-21 Kennecott Copper Corp Process for production of ultra-high purity rhenium
US3260658A (en) * 1962-10-31 1966-07-12 Philip E Churchward Process for the recovery of rhenium
US3870779A (en) * 1973-10-10 1975-03-11 Kennecott Copper Corp Process of recovering rhenium values from complex industrial solutions
CA2214089A1 (en) * 1996-08-26 1998-02-26 Wei Jia Production of 186re, 188re and other radionuclides via inorganic szilard-chalmers process
US5862193A (en) * 1997-08-20 1999-01-19 The Curators Of The University Of Missouri Production of 186 Re, 188 Re and other radionuclides via inorganic szilard-chalmers process
US5796897A (en) 1997-02-06 1998-08-18 Wave Optics, Inc. Universal adaptor for keyed fiberoptic connectors
WO2000006243A2 (en) * 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
CN1075389C (zh) * 1999-05-14 2001-11-28 中国科学院上海原子核研究所 铼核素标记碘化油溶胶制剂、制备方法及其应用
RU2159296C1 (ru) * 1999-06-10 2000-11-20 Институт минералогии, геохимии и кристаллохимии редких элементов Способ извлечения рения и других металлов
RU2222626C1 (ru) * 2002-05-07 2004-01-27 Государственное унитарное предприятие "Всероссийский научно-исследовательский институт химической технологии" Способ извлечения рения и других элементов
US20040197264A1 (en) * 2003-04-04 2004-10-07 Alexander Schwarz Microspheres comprising therapeutic and diagnostic radioactive isotopes
WO2005018681A1 (en) * 2003-06-03 2005-03-03 The Trustees Of The University Of Pennsylvania Nanoradiopharmaceuticals and methods of use
EP2142284A4 (en) 2007-03-31 2015-12-23 Advanced Applied Physics Solutions Inc METHOD AND DEVICE FOR INSULATING 186RHENIUM
US8821364B2 (en) * 2008-09-02 2014-09-02 Battelle Memorial Institute Brachytherapy seed with fast dissolving matrix for optimal delivery of radionuclides to cancer tissue
CN102671219B (zh) * 2011-03-11 2013-12-11 成都云克药业有限责任公司 一种放射性阴离子树脂微球及其制备方法
DE102011050848B4 (de) * 2011-06-06 2015-10-01 ITM Isotopen Technologien München AG Schichtaufbau zur epidermalen Radionuklidtherapie
RU2481660C1 (ru) * 2011-12-29 2013-05-10 Федеральное государственное унитарное предприятие "Государственный научный центр Российской Федерации - Физико-энергетический институт имени А.И. Лейпунского" Способ получения генераторного радионуклида рений-188
TWI538690B (zh) * 2011-12-30 2016-06-21 行政院原子能委員會核能研究所 一種製備錸－１８８或錸－１８６人類血清白蛋白微球體之方法及套件與該套件之使用方法
RU2476942C1 (ru) * 2012-01-10 2013-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Национальный исследовательский Томский политехнический университет" Способ получения радионуклида рений-188 без носителя и устройство для его осуществления
WO2014159759A1 (en) * 2013-03-13 2014-10-02 Biosphere Medical, Inc. Compositions and associated methods for radioisotope-binding microparticles
CN105288743B (zh) * 2014-07-23 2018-08-21 上海交通大学医学院附属第九人民医院 放射性核素标记的介孔生物玻璃纳米颗粒及其制备方法与应用
RU2621516C1 (ru) 2016-02-25 2017-06-06 Общество с ограниченной ответственностью "Институт вулканологии и геодинамики" Способ извлечения рения и других элементов

Also Published As

Publication number Publication date
AU2017343616A1 (en) 2019-05-16
CN110168669A (zh) 2019-08-23
RU2749141C2 (ru) 2021-06-07
PL3523811T3 (pl) 2021-10-11
CN110168669B (zh) 2023-10-27
BR112019007308A2 (pt) 2019-07-02
AU2017343616B2 (en) 2022-07-21
IL265932B (en) 2022-04-01
CO2019004738A2 (es) 2019-05-21
US20190290789A1 (en) 2019-09-26
US11135323B2 (en) 2021-10-05
DE102016119239A1 (de) 2018-04-12
IL265932A (en) 2019-05-30
EP3523811A1 (en) 2019-08-14
NZ752287A (en) 2023-07-28
EP3523811B1 (en) 2021-04-14
RU2019113502A3 (es) 2020-11-13
KR102488513B1 (ko) 2023-01-12
RU2019113502A (ru) 2020-11-13
KR20190058645A (ko) 2019-05-29
CA3039834A1 (en) 2018-04-19
WO2018069329A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
UY37703A (es) Compuestos heteroarílicos bicíclicos 6-6 fusionados y su uso como inhibidores de lats
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
EA201792613A1 (ru) Модуляторы cot и способы их применения
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
BR112018003186A2 (pt) anticorpos anti-pd-1 e seus métodos de uso
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
CR20150314A (es) Pirimido-[4,5-b]-quinolina-4,5 (3h, 10h)-dionas como supresoras de mutación sin sentido
BR112017027887A2 (pt) partículas e suspensões radioterapêuticas
ECSP16096831A (es) Derivados de naftiridinadiona
ECSP17013904A (es) Angiopoietin-like 4 antibodies and methods of use
CL2020001137A1 (es) Anticuerpos anti-apoc3 y métodos de uso de estos.
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
CL2019000951A1 (es) Producción de partículas re-188/186
CL2020001675A1 (es) Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
MY182398A (en) Cosmetic product comprising water-insoluble sponge impregnated with cosmetic composition having ultraviolet ray blocking function
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
BR112016012002A2 (pt) Vitanolídeos úteis para o tratamento de doenças neurodegenerativas
UY37064A (es) Método de purificación
UY37065A (es) Método de purificación
CO2021015462A2 (es) Anticuerpos y formulaciones de anti-cd38